TARA
Protara Therapeutics, Inc.
Related News
SEC Filings
Earnings Trend
Screening
Compare
Economic Calendar
We use cookies in accordance with European GDPR standards to improve site usability, analytics, and deliver personalized advertising.Learn moreCookie Settings
Protara Therapeutics is rated Buy, with a risk-adjusted fair value of $9.96 per share versus the current $4 price. TARA-002 targets NMIBC and Lymphatic Malformations; orphan drug indications offer si
